FYN (Y531F)
Sign in to save this workspaceFYN · Variant type: point · HGVS: p.Y531F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Bosutinib | 100.0% | 0.0% | 87.22 |
| 2 | Ponatinib | 100.0% | 0.0% | 78.23 |
| 3 | Nintedanib | 100.0% | 0.0% | 90.23 |
| 4 | Dasatinib | 100.0% | 0.0% | 87.97 |
| 5 | Repotrectinib | 99.3% | 0.7% | 84.21 |
| 6 | Entrectinib | 95.1% | 4.9% | 93.69 |
| 7 | Brigatinib | 93.3% | 6.7% | 82.96 |
| 8 | Vandetanib | 92.9% | 7.1% | 95.74 |
| 9 | Crizotinib | 92.2% | 7.8% | 91.39 |
| 10 | Ibrutinib | 90.1% | 9.9% | 94.74 |
| 11 | Gilteritinib | 89.8% | 10.2% | 88.97 |
| 12 | Pacritinib | 86.6% | 13.4% | 88.64 |
| 13 | Dabrafenib | 84.9% | 15.1% | 94.74 |
| 14 | Vemurafenib | 84.6% | 15.4% | 96.49 |
| 15 | Sunitinib | 81.3% | 18.7% | 91.73 |
| 16 | Fostamatinib | 78.8% | 21.2% | 96.74 |
| 17 | Alectinib | 78.1% | 21.9% | 95.49 |
| 18 | Dacomitinib | 78.0% | 22.0% | 97.99 |
| 19 | Pralsetinib | 76.7% | 23.3% | 93.43 |
| 20 | Canertinib | 73.2% | 26.8% | 96.49 |
| 21 | Tivozanib | 69.8% | 30.2% | 92.42 |
| 22 | Erdafitinib | 66.5% | 33.5% | 95.71 |
| 23 | Neratinib | 63.1% | 36.9% | 93.18 |
| 24 | Ripretinib | 62.9% | 37.1% | 92.95 |
| 25 | Fedratinib | 58.9% | 41.1% | 96.21 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Bosutinib | 100.0% | 99.7% | +0.3% |
| Ponatinib | 100.0% | 99.4% | +0.6% |
| Nintedanib | 100.0% | 95.6% | +4.4% |
| Dasatinib | 100.0% | 100.0% | +0.0% |
| Repotrectinib | 99.3% | 97.1% | +2.2% |
| Entrectinib | 95.1% | 82.0% | +13.1% |
| Brigatinib | 93.3% | 73.9% | +19.4% |
| Vandetanib | 92.9% | 75.6% | +17.2% |
| Crizotinib | 92.2% | 53.3% | +38.9% |
| Ibrutinib | 90.1% | 92.1% | -2.0% |
| Gilteritinib | 89.8% | 85.9% | +3.9% |
| Pacritinib | 86.6% | 92.2% | -5.6% |
| Dabrafenib | 84.9% | — | — |
| Vemurafenib | 84.6% | 54.7% | +29.9% |
| Sunitinib | 81.3% | — | — |
| Fostamatinib | 78.8% | — | — |
| Alectinib | 78.1% | — | — |
| Dacomitinib | 78.0% | — | — |
| Pralsetinib | 76.7% | — | — |
| Canertinib | 73.2% | 61.4% | +11.9% |
| Tivozanib | 69.8% | 67.5% | +2.3% |
| Erdafitinib | 66.5% | — | — |
| Neratinib | 63.1% | 66.0% | -3.0% |
| Ripretinib | 62.9% | 84.0% | -21.0% |
| Fedratinib | 58.9% | 83.5% | -24.6% |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| AML-US | Blood/Lymphatic System | ref |
| glioma_central_nervous_system | Brain/CNS | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 19.6ms